

FDLI Enforcement Conference How to Respond to a BIMO Inspection: During & After

Heidi Gertner, Partner, Hogan Lovells

December 6, 2017



FDA's Bioresearch Monitoring (BIMO) Program

• Protecting the rights, safety and welfare of research subjects

- Begins with the development of the trial concept
- Is incorporated into all stages of a clinical trial

Compliance with FDA regulations

- Protection of human subjects is integral to FDA's mission, statutes and regulations
- FDA and other regulators cannot ensure HSP by themselves
- HSP is a collaborative effort
- Familiarize yourself with applicable FDA regulations, guidances, and BIMO Compliance Programs

Quality and integrity of data

 Data integrity is dependent on careful planning and execution throughout every phase of clinical trial

What are the BIMO inspectors looking for?

- In short, they are **assessing compliance**
- Violations can be found in your:
 - Case report forms
 - Are there protocol violations?
 - Are the dates / signatures correct?
 - Copies of signed informed consent documents
 - Was informed consent documented properly?
 - Was the version used correct?
 - Drug disposition records
 - IRB study files
 - IRB meeting minutes
 - Your written policies and procedures



Common mistakes researchers make...

- The most common violations in 2016 for investigators were:
 - (1) failure to follow the investigational plan and/or regulation;
 - (2) protocol deviations;
 - (3) inadequate recordkeeping;
 - (4) inadequate accountability for the investigational product;
 - (5) inadequate communication with the IRB;
 - (6) inadequate subject protection failure to report adverse events and informed consent issues; and
 - (7) investigational product represented as safe and effective.

Common mistakes IRBs make...

- The most common IRB deficiencies in 2016 included:
 - (1) inadequate initial and/or continuing review;
 - (2) inadequate written procedures;
 - (3) inadequate meeting minutes, membership rosters;
 - (4) quorum issues;
 - (5) prompt reporting of noncompliance, suspension/termination;
 - (6) Subpart D issues; and
 - (7) lack of or incorrect SR or NSR determination.

What happens if you have regulatory violations? This is serious business.

- FDA's administrative actions and enforcement tools
 - To investigators and/or sponsors:
 - Place study on clinical hold or stop study—see 21 CFR 312.42 and 21 CFR 812.30
 - Warning or Untitled letter
 - Investigator Disqualification—see 21 CFR 312.70 and 21 CFR 812.119
 - Occurs when FDA has information indicating that an investigator has repeatedly or deliberately failed to comply with 21 CFR Parts 50, 56, or 312/812, or has repeatedly or deliberately submitted to FDA or the sponsor false information in any required report
 - Investigator Debarment (criminal violations)
 - To IRBs:
 - Lesser administrative actions, usually in the form of a noncompliance letter—see 21 CFR 56.120
 - IRB disqualification—see 21 CFR 56.121

What should you do (and how should you behave) when the government shows up...

- whether it's:
 - FDA, OHRP, ORI, DOJ...

RULES ARE RULES.

- whether it's:
 - for cause, unannounced, routine...

...try to set yourselves up for the best possible outcome.

Your goals...

- To get through the inspection without any findings of violations; or
- To get through the inspection with minimal findings that will not generate an enforcement action; or
- To get through the inspection with findings that you can develop a plan to address that will be acceptable to the government; and
- To stay out of the news.



If you have advance notice (or even if you don't,

when you get a chance):

- Prep your people
 - Appropriate behavior
 - Be polite
 - Be respectful
 - Take the inspection seriously
 - Tell them to be sure that they:
 - Understand questions; don't speculate
 - Answer what asked only; don't offer additional information
 - Are truthful
 - Don't admit wrongdoing; you'll have time to acknowledge shortcomings later in a well thought-out response
 - Let them know you support them
- Discuss with your legal department

During the inspection...

- Set the right tone
 - <u>Do not be:</u>
 - Defensive
 - Secretive
 - Pointing fingers
 - <u>Do be:</u>
 - Respectful
 - Helpful
 - Open to critique
 - Open to suggestion
 - Open to improving your research program

During the inspection...

- Get the right team together
 - Figure out key personnel who should be involved
 - Have a specific person(s) assigned to meet with the inspectors, answer questions, provide documents
 - Have a separate note taker (for each inspector) to transcribe comments, observations, etc.
- Have additional members of the team working on:
 - Locating documents
 - Keeping binders and a log of all documents and materials provided
 - Finding answers to questions
 - Attempting to predict outcome
 - Preparing for ultimate response

During the inspection...

- At the end of each day of the inspection
 - Meet with team to debrief
 - Continue to locate any needed documents
 - Find answers to unanswered questions
 - If violations are being found:
 - Think about your response



- Are they mistaken? Do you have an explanation or justification?
- How could you change your program to avoid these problems in the future?
 - Better institutional support? Training? Monitoring/oversight? Organization?
- Have good communication with your people and the inspectors

At the closeout and just after...

- As the inspectors finish up:
 - Stay calm
 - Accept the oral findings (usually written findings arrive a few days later)
 - Understand their timeline/process
- After they leave:
 - This is your small window to change the outcome of any written findings of violations
 - Are there additional documents that would support your cause?
 - Are there additional explanations that would support your cause?

- You still have an opportunity to avoid being the subject of an enforcement action
 - Submit any additional information
- Develop a clear, point by point response to the 483
- Think about the components of a comprehensive action plan
 - Training of staff
 - Better oversight
 - Being responsible for less studies
 - Put mentors in place
- What will your follow up reporting plan look like?

- Start preparing for drafting the response letter while the inspection team is still on site
 - Try to anticipate what the 483 will state **before** you receive it
 - Gather key documents
 - Determine who will write the first draft of the response letter
 - Compliance personnel
 - Investigators and staff
 - General counsel's office/outside counsel

- Plan for the logistics
 - Determine the signatory(ies) of the response letter
 - Calculate the due date
 - Know the recipient of the response
 - Determine how you will transmit the response
 - Keep all information where team members can find it easily

- Set the Tone
 - Show that the agency's findings have been taken seriously
 - Avoid defensive statements and/or trying to place blame on third parties
 - If the 483 included a factual statement that is incorrect AND you have solid evidence to prove the mistake, correct the error in a respectful manner
 - Avoid discussing the strength of your existing policies and procedures

- Not the time for creative writing
 - Respond in a point-by-point manner to all agency findings
 - Respond completely
 - Create a cross-walk of the findings letter and your response
 - Make sure that your narrative makes logical sense and is backed by evidence
- Goal is to avoid receiving a request for additional information

- Do you understand fully the problems that led to the regulatory findings?
 - If not, organize an internal investigation to determine the **<u>root cause</u>**
 - In your response letter:
 - Describe the nature of the investigation
 - Explain your plan for reporting the findings of the investigation to the agency

- Determine what needs to be changed
 - Driven by what the inspection team found
 - Were policies and procedures deficient, or did investigators and staff fail to follow the policies and procedures in place?
 - In the former situation, policies and procedures may need to be revised
 - In the latter, re-training of staff and investigators may be needed
 - Determine a plan for ongoing monitoring and follow-up reporting (if appropriate)

- Create a timeline for your action plan
 - Describe in the response letter a target date by which certain activities will be completed, *e.g.*, completion of staff re-training
 - Make the target date achievable—the agency may ask you in a follow-up letter for proof that certain activities were completed timely
 - Offer to provide some of the materials in a follow-up letter

- Work does <u>not</u> end just because response letter has been submitted
 - Create a tracking mechanism to monitor completion of all promises made in the response letter
 - Document all steps taken
 - Revised drafts of policies
 - Training materials
 - Records of attendance at training sessions
 - Evaluation materials used during training

- What did agency miss that might come up next time?
 - Use the momentum for change to revise other practices that may be deficient
 - Do not mention these additional findings in your response letter to the agency, *i.e.*, avoid temptation to "overshare"

Role of Counsel

- Counsel can provide an outside, objective perspective during response process
 - Counsel can take a lead role in organizing documents and interviewing personnel
 - Use of counsel can maintain internal investigation under privilege
 - Counsel can take lead in drafting response letter and incorporating comments from key stakeholders
- Counsel can help manage corrective actions
 - Manage the timeline to ensure tasks are completed on time
 - Convene meetings to discuss policies that need to be reviewed
 - Redraft policies that need modifications



Just ask!



Thank you!



Heidi F. Gertner, Partner Washington, DC

heidi.gertner@hoganlovells.com 202.637.5910





www.hoganlovells.com

"Hogan Lovells" or the "firm" is an international legal practice that includes Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses.

The word "partner" is used to describe a partner or member of Hogan Lovells International LLP, Hogan Lovells US LLP or any of their affiliated entities or any employee or consultant with equivalent standing. Certain individuals, who are designated as partners, but who are not members of Hogan Lovells International LLP, do not hold qualifications equivalent to members.

For more information about Hogan Lovells, the partners and their qualifications, see www.hoganlovells.com.

Where case studies are included, results achieved do not guarantee similar outcomes for other clients. Attorney advertising. Images of people may feature current or former lawyers and employees at Hogan Lovells or models not connected with the firm.

© Hogan Lovells 2017. All rights reserved